Diabetes PubMed

  • Increase font size
  • Default font size
  • Decrease font size
Home Medication Biguanides Metformin Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus

Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus

Nutr Metab (Lond). 2010 Nov 12;7(1):83

Authors: Ito H, Ishida H, Takeuchi Y, Antoku S, Abe M, Mifune M, Togane M

ABSTRACT: BACKGROUND: We aimed to investigate the long-term effect of metformin on the blood glucose control in non-obese patients with type 2 diabetes mellitus. METHODS: A retrospective study was performed in 213 patients with type 2 diabetes mellitus under the administration of metformin for more than one year. The clinical parameters were investigated for 3 years. The obese and non-obese individuals were defined as a body mass index (BMI) of 25 kg/m2 or over (n = 105) and a BMI of less than 25 kg/m2 (n = 108), respectively. RESULTS: HbA1c levels were significantly decreased compared with those at the baseline time. The course of HbA1c was similar between the non-obese and the obese groups, while the dose of metformin required to control blood glucose was significantly lower in the non-obese group than in the obese group. The reductions in HbA1c were 1.2% and 1.1% at 12 months, 0.9% and 0.9% at 24 months, and 0.8% and 1.0% at 36 months in the non-obese and obese groups, respectively. BMI did not change during the observation periods. Approximately half of all patients required no additional antidiabetic agents or a reduction in other treatments after the initiation of metformin in either of the two groups. CONCLUSIONS: The present study demonstrated the long-term beneficial effect of metformin in non-obese (BMI < 25 kg/m2) diabetic patients. This effect appears to be maintained even after the observation period of this study, because metformin was limited to a relatively low dose in the non-obese group and the observed worsening in glycemic control over time can probably be attenuated by increasing the dose of metformin.

PMID: 21070671

 

Bookmark and Share

Popular Diabetes PubMed Citations

Newsflash

Millions unite for diabetes awareness on World Diabetes Day 2010
Starting today, people from all corners of the world are uniting together for three days of celebration to put diabetes firmly in the public spotlight. World Diabetes Day is the best opportunity there is to draw attention to the silent killer that is diabetes.
 
Bristol-Myers Squibb Foundation Launches $100 Million Initiative
The Bristol-Myers Squibb Foundation announced Together on Diabetes®: Communities Uniting to Meet America's Diabetes Challenge, a 5-year, $100 million initiative to help patients living with type 2 diabetes better manage their disease beyond the doors of their doctor's office - in their homes and communities - and for the course of their disease.
 
New global survey reveals more than one in three patients fail to take insulin as prescribed
More than one in three diabetes patients skip doses or fail to take their insulin as prescribed, stating that they have done so on average three times in the last month, and 77% of physicians estimate that in reality this number could be as high as six doses*, according to the Global Attitudes of Patients and Physicians in Insulin Therapy (GAPPTM) survey, released today by Novo Nordisk.
 

Facebook Page Twitter Subscribe to Latest Diabetes PubMed facts... by Email RSS

Subscribe

Get Diabetes PubMed facts delivered by email. Enter your email address:


Delivered by FeedBurner

Who's Online

We have 6 guests online

Sponsored Links

PharmaNews.eu
PharmaNews.eu - the dynamic European pharmaceutical news engine.
www.pharmanews.eu

Advertise here